

Press Release

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

November 17, 2021, Berlin. Ahead of the "World Antimicrobial Awareness Week" (18-24 November) 20 national and international organisations from academia, healthcare, [global health](#) and the pharmaceutical industry appealed today to G7 governments to step up efforts to tackle the [growing](#) problem [of antibiotic resistance](#). Their "Joint Statement on Strengthening the Antibiotic R&D Pipeline by Rewarding Innovation" stresses that only an approach involving both the public and private sectors is likely to succeed.

The [signatories](#) emphasise that it is important to ensure that more incentives are provided for research and development on new anti-bacterial drugs, that new antibiotics against [hard to treat](#) infections reach patients quickly, that the potential of vaccines to reduce the risk of bacterial infections is fully exploited, and that antibiotics that are still effective today are used even more carefully.

In 2022, during its G7 presidency, Germany will have the opportunity to work toward progress and ensure that solutions continue to be worked [on during](#) the subsequent Japanese presidency in 2023.

[Strengthening the response to antibiotic resistance](#)

Because the problem is multifaceted, the signatories [of the joint statement](#) see the need for different measures, some adapted to the health systems of individual countries. Two examples:


In order to strengthen research and development, incentives are needed that provide economic rewards for successfully developed antibiotics against [drug-resistant infections – in addition to](#) the current funding support for individual stages of the research and development process prior to approval.

In Europe, access to the latest antibiotics for patients in need is often hampered by the lack of adequate coverage by health insurance or public health care.

Signatories

The "Joint Statement" was signed by: AMR Action Fund, AMR Alliance, BAG Selbsthilfe, Bundesverband der Arzneimittelhersteller (BAH), BEAM Alliance, Bundesverband der Deutschen Industrie (BDI), Bundesverband der Pharmazeutischen Industrie (BPI), Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO), Deutsche Gesellschaft für Infektiologie (dgi), German Center for

GLOBAL AMR R&D HUB



Infection Research (DZIF), Global Antibiotic Research & Development Partnership (GARDP), German Health Alliance, Global AMR R&D Hub, Helmholtz Association of German Research Centers, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Paul Ehrlich Gesellschaft für Chemotherapie (PEG), Prof. Dr. Detlev Ganten, Sepsis Stiftung, German Association of Research-Based Pharmaceutical Companies (vfa), World Health Summit.

Further information

The "Joint Statement" can be found at: <https://tinyurl.com/43bk27kj>

Information on the "World Antimicrobial Awareness Week" (Nov. 18-24, 2021) is provided by: <https://www.who.int/news-room/events/detail/2021/11/18/default-calendar/world-antimicrobial-awareness-week-2021>

Media contact

Dr Ralf Sudbrak
Senior Scientific Programme Officer
Global AMR R&D Hub
Ralf.sudbrak@dzif.de
+49-30 403 677 76